Corbus In-Licenses Two Anti-Integrin Antibodies Targeting Cancer, Fibrotic Diseases Settings

Vandana Singh
1 min read
0
In this article:

  • Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has announced licensing deals for two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of transforming growth factor β (TGFβ).

  • TGFβ is a multifunctional cytokine involved in many cellular processes, including cell growth and differentiation, immune responses, wound healing, and tissue repair.

  • CRB-601 is an anti- α vβ8 mAb expressed by cancer cells. Corbus plans to develop CRB-601 to treat solid tumors in combination with existing therapies, including checkpoint inhibitors.

  • CRB-602 specifically inhibits both αvβ6 and αvβ8 implicated in fibrotic diseases and cancers of epithelial cell origin.

  • Both the programs are expected to enter Phase 1 studies in 2022.

  • The Company's $125 million cash and investments on hand, as of March 31, is expected to fund operations into the first quarter of 2024.

  • Under the combined terms of the two exclusive licensing agreements, Corbus will pay $2 million upfront, make potential milestone payments of up to $206 million, and pay low single-digit royalties on sales.

  • Price Action: CRBP shares are 6.68% lower at $2.03 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories